IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Two Sigma Securities LLC

Two Sigma Securities LLC lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 66.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,664 shares of the medical research company's stock after selling 3,275 shares during the period. Two Sigma Securities LLC's holdings in IQVIA were worth $327,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of IQV. Synergy Asset Management LLC acquired a new stake in IQVIA during the 4th quarter worth approximately $33,000. GKV Capital Management Co. Inc. acquired a new stake in IQVIA in the 4th quarter valued at $39,000. Lee Danner & Bass Inc. bought a new stake in IQVIA during the 4th quarter worth approximately $44,000. Zions Bancorporation N.A. lifted its position in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares in the last quarter. Finally, Versant Capital Management Inc grew its stake in IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after purchasing an additional 93 shares during the period. Institutional investors own 89.62% of the company's stock.

IQVIA Price Performance

IQVIA stock traded down $4.05 during mid-day trading on Thursday, reaching $151.02. 1,841,714 shares of the company's stock traded hands, compared to its average volume of 1,433,556. The company has a market cap of $26.63 billion, a price-to-earnings ratio of 20.14, a PEG ratio of 1.99 and a beta of 1.46. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a 50 day moving average of $169.14 and a two-hundred day moving average of $192.46. IQVIA Holdings Inc. has a 12-month low of $135.97 and a 12-month high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Citigroup lowered their price objective on IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Barclays reaffirmed an "equal weight" rating and set a $170.00 price objective (down from $235.00) on shares of IQVIA in a research note on Thursday, April 10th. Stifel Nicolaus dropped their price objective on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a report on Friday, February 7th. Mizuho reduced their price target on IQVIA from $242.00 to $210.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 9th. Finally, HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and dropped their price target for the stock from $260.00 to $160.00 in a research note on Friday, April 25th. Eight equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $237.62.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.